IGC Pharma Inc

IGC Pharma expands its Phase II CALMA trial to Colombia, boosting diversity and investor confidence, while a positive equity research update sets a $3.00 price target for the company’s Alzheimer’s drug.

IGC Pharma Inc. is a pioneering biopharmaceutical company focused on developing cannabinoid-based formulations to address various diseases and conditions, positioning itself as a key player in the evolving healthcare industry.

IGC Pharma Inc. is a biopharmaceutical company pioneering cannabinoid-based therapies for conditions such as Alzheimer’s, menstrual cramps, and chronic pain, offering a glimpse into the future of healthcare.